source
- Akeso's ivonescimab shows survival advantage over Keytruda in Chinese lung cancer trialA new data cut from a study comparing ivonescimab, a bispecific antibody from China-based Akeso, with Merck's Keytruda in patients with non-small cell lung cancer was released. The interim results…
- Boston Scientific recalls Infinion CX spinal cord stimulator leads over risk of mechanical stress and fractureBoston Scientific issued a recall of its Infinion CX spinal cord stimulator leads after identifying a risk of mechanical stress at the anchor site that can cause high impedance readings or lead fra…